ImmunoGen, Inc.
CIK 0000855654
Revenue (TTM)
—
Q3 Oct 2023
Net Income (TTM)
−$73.52M
−60.0% YoY
Q3 Oct 2023
EPS Diluted (TTM)
−$0.55
−29.4% YoY
Q3 Oct 2023
Gross Margin
—
Q3 Oct 2023
Operating Margin
—
Q3 Oct 2023
Net Margin
—
Q3 Oct 2023
Free Cash Flow (TTM)
−$189.49M
Q3 Oct 2023
Cash
$605.54M
Q3 Oct 2023
Total Debt
—
Q3 Oct 2023
Shares Outstanding
266.26M sh
Q3 Oct 2023
Revenue & Net Income
EPS (Diluted)
Cash Flow
Revenue Growth (YoY)
No data available for this metric.